# Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies

> **NCT03031938** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 4 (actual)

## Conditions studied

- Osteoarthritis
- Cancer Pain
- Recurrent Low Back Pain

## Interventions

- **DRUG:** Investigational medical product (IMP) administered in parent study

## Key facts

- **NCT ID:** NCT03031938
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-03
- **Primary completion:** 2020-06-04
- **Final completion:** 2020-06-04
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2021-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03031938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03031938, "Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03031938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*